Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells

Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differentiation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis in hematologic and lymphoid malignancie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Cain, Jason E., McCaw, Andrew, Jayasekara, W. Samantha N., Rossello, Fernando J., Marini, Kieren D., Irving, Aaron T., Kansara, Maya, Thomas, David M., Ashley, David M., Watkins, D. Neil
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2013
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3603321/
https://ncbi.nlm.nih.gov/pubmed/23533324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/608964
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi